Key facts
- Pangea Bio’s last known valuation is $80.0M (Oct 2024).
- It has raised $21.7M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($15.6M) in Oct 2023.
- Notable investors include Plug and Play Tech Center, Innovate UK, Metaplanet Holdings, London & Partners., Hub71 — 19 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Pangea Bio
Funding rounds
1 roundsAbout Pangea Bio
Developer of a novel medicines platform designed to treat neurological disorders. The company's platform uses artificial intelligence to uncover promising molecules from nature's diverse chemical space, enhanced by traditional human evidence of safety and efficacy, enabling healthcare providers to accelerate the development of new medicines for central nervous system disorders.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Kent, United Kingdom
- Founded
- 2021
- Employees
- 28
- Website
- pangeabio.com/
- Ownership
- Privately Held (backing)
Pangea Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pangea Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pangea Bio in its N-PORT filings yet. We sweep new filings monthly.